Drug intelligence / Profile preview

BP1.3656

Development stage: Phase 2
Lead developer: Bioprojet
Modality: Small Molecules
Administration: Oral

Overview

BP1.3656 is a novel histamine H3 receptor antagonist being developed by Bioprojet Pharma. It is primarily being investigated for the treatment of alcohol use disorder (AUD) and fatigue, including post-stroke fatigue. Preclinical studies in rats have shown that BP1.3656 significantly decreases alcohol self-administration in alcohol-dependent rats and reduces reinstatement behaviors.

Targets

HRH3 (Histamine Receptor H3)

Beyond the preview

Go deeper on BP1.3656.

Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from study design and recruitment through results.

Trial phase
Status
Readouts

Indications & development

Explore development by indication, patient population, and geography.

Indications
Development status
Countries

Licensing & deals

Trace asset ownership, licensing agreements, and commercial partnerships.

Partners
Deal terms
Milestones

Patents & exclusivity

Explore the patent landscape and regulatory exclusivity around an asset.

Patents
Expiration dates
Exclusivity

Competitive landscape

Compare development programs by target, modality, and indication.

Competing assets
Targets
Development stage

Research & analysis

Connect source evidence and development news to your research questions.

Publications
News
Analysis

Bring the full picture into focus.

See how Gosset can support your research on BP1.3656.

Explore the full profile